|
  
- 积分
- 97
- 威望
- 97
- 包包
- 3142
|
本帖最后由 bobo 于 2009-6-28 08:34 编辑 ) M ^6 ^- ~ p, y7 [7 b
, I0 g# S$ ^" }
表观遗传学与干细胞——2009年亚洲生物高峰论坛录制(音频mp3)
* p4 F% n7 Z7 a7 N- S
% i6 I( l( V' N! Z( n, ~
, i7 Z5 E& c! G. {0 r) d6 s& _5 u" v( m2 h! `' u8 z* N/ Y
回复为ppt) @- j, B+ z: q1 s0 B8 j
摘要：
: r2 f* N1 A: _
4 x- |) ^8 ]2 e/ xHongkui Deng
0 k0 t: o& c5 i/ P+ D. g3 M5 G( q4 B8 ^' z1 s& Y- g/ l
Laboratory of Stem Cell and Generative Biology, College of Life Sciences, Peking University, Beijing 100871, China.5 D e$ T5 Y9 r
1 T1 O, R5 G% _7 mHuman pluripotent stem cells represent a potentially unlimited source of functional pancreatic endocrine lineage cells. We established a new highly efficient approach to induce human embryonic stem （ES） cells and induced pluripotent stem （iPS） cells to differentiate into mature insulin-producing cells in a chemical-defined culture system. The differentiated cells obtained by this approach comprised nearly 25% insulin-positive cells as assayed by flow cytometry analysis, which released insulin/C-peptide in response to glucose stimuli in a manner comparable to that of adult human islets. Most of these insulin-producing cells co-expressed mature beta cell-specific markers such as NKX6-1 and PDX1, indicating a similar gene expression pattern to adult islet beta cells in vivo. This work provides a new model to study the mechanism of human pancreatic specialization and maturation in vitro, and enhances the possibility of utilizing patient-specific iPS cells for the treatment of diabetes( v; M% w! O' G3 ]
* p5 D3 y( j( H$ }) M2 _; @回复为ppt
* B6 q: q, b0 p! M3 g# ^! H4 \0 j/ q% E6 ~1 y
3 Q1 T$ {# c+ a: p
( {* P7 e! K" K+ u; E5 q
4 k6 O# E9 H5 L' N9 l$ m& q+ } y
|
附件: 你需要登录才可以下载或查看附件。没有帐号？注册
|
发表于 2009-6-28 08:19
发表于 2009-8-7 16:10
